PNC Financial Services Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$32.1M Buy
71,942
+2,517
+4% +$1.17M 0.02% 357
2025
Q4
$31.5M Sell
69,425
-347
-0.5% -$150K 0.02% 349
2025
Q3
$27.3M Sell
69,772
-6,384
-8% -$2.67M 0.02% 367
2025
Q2
$33.9M Sell
76,156
-2,005
-3% -$924K 0.02% 328
2025
Q1
$37.9M Sell
78,161
-461
-0.6% -$215K 0.02% 304
2024
Q4
$31.7M Sell
78,622
-807
-1% -$374K 0.02% 317
2024
Q3
$36.9M Buy
79,429
+4,269
+6% +$2.05M 0.02% 306
2024
Q2
$35.2M Sell
75,160
-4,794
-6% -$2.08M 0.02% 305
2024
Q1
$33.4M Buy
79,954
+3,258
+4% +$1.38M 0.02% 314
2023
Q4
$31.2M Buy
76,696
+2,431
+3% +$898K 0.02% 311
2023
Q3
$25.8M Buy
74,265
+1,573
+2% +$550K 0.02% 325
2023
Q2
$25.6M Buy
72,692
+4,480
+7% +$1.51M 0.02% 341
2023
Q1
$21.5M Sell
68,212
-2,063
-3% -$619K 0.02% 365
2022
Q4
$20.3M Sell
70,275
-2,328
-3% -$710K 0.02% 370
2022
Q3
$21M Buy
72,603
+1,248
+2% +$359K 0.02% 355
2022
Q2
$20.1M Buy
71,355
+191
+0.3% +$51.1K 0.02% 367
2022
Q1
$18.6M Buy
71,164
+19,627
+38% +$4.66M 0.02% 407
2021
Q4
$11.3M Buy
51,537
+20,397
+66% +$3.97M 0.01% 513
2021
Q3
$5.65M Buy
31,140
+1,524
+5% +$298K 0.01% 629
2021
Q2
$5.97M Sell
29,616
-110
-0.4% -$23K 0.01% 614
2021
Q1
$6.39M Sell
29,726
-15,956
-35% -$3.5M 0.01% 577
2020
Q4
$10.8M Sell
45,682
-1,789
-4% -$410K 0.01% 476
2020
Q3
$12.9M Buy
47,471
+1,575
+3% +$435K 0.02% 412
2020
Q2
$13.3M Buy
45,896
+21,649
+89% +$5.87M 0.02% 397
2020
Q1
$5.77M Buy
24,247
+857
+4% +$197K 0.01% 516
2019
Q4
$5.12M Buy
23,390
+33
+0.1% +$6.68K 0.01% 603
2019
Q3
$3.96M Sell
23,357
-1,636
-7% -$289K ﹤0.01% 723
2019
Q2
$4.58M Sell
24,993
-1,042
-4% -$182K ﹤0.01% 731
2019
Q1
$4.79M Buy
26,035
+1,200
+5% +$222K ﹤0.01% 727
2018
Q4
$4.12M Sell
24,835
-6,915
-22% -$1.2M ﹤0.01% 743
2018
Q3
$6.12M Buy
31,750
+8,707
+38% +$1.55M 0.01% 698
2018
Q2
$3.92M Sell
23,043
-1,825
-7% -$283K ﹤0.01% 830
2018
Q1
$4.05M Buy
24,868
+1,108
+5% +$181K ﹤0.01% 797
2017
Q4
$3.56M Sell
23,760
-2,145
-8% -$318K ﹤0.01% 847
2017
Q3
$3.94M Buy
25,905
+3,419
+15% +$515K ﹤0.01% 790
2017
Q2
$2.9M Buy
22,486
+1,486
+7% +$179K ﹤0.01% 869
2017
Q1
$2.3M Buy
21,000
+3,527
+20% +$311K ﹤0.01% 956
2016
Q4
$1.29M Sell
17,473
-6,660
-28% -$542K ﹤0.01% 1170
2016
Q3
$2.1M Buy
24,133
+3,069
+15% +$290K ﹤0.01% 962
2016
Q2
$1.81M Buy
21,064
+4,179
+25% +$361K ﹤0.01% 986
2016
Q1
$1.34M Buy
16,885
+3,182
+23% +$288K ﹤0.01% 1127
2015
Q4
$1.73M Sell
13,703
-22,583
-62% -$2.73M ﹤0.01% 970
2015
Q3
$3.78M Buy
36,286
+1,039
+3% +$133K ﹤0.01% 706
2015
Q2
$4.35M Sell
35,247
-825
-2% -$104K ﹤0.01% 709
2015
Q1
$4.26M Buy
36,072
+2,061
+6% +$247K ﹤0.01% 709
2014
Q4
$4.04M Buy
34,011
+5,988
+21% +$674K ﹤0.01% 715
2014
Q3
$3.15M Buy
28,023
+13,111
+88% +$1.25M ﹤0.01% 764
2014
Q2
$1.41M Sell
14,912
-430
-3% -$30.2K ﹤0.01% 978
2014
Q1
$1.08M Sell
15,342
-2,329
-13% -$184K ﹤0.01% 1040
2013
Q4
$1.31M Sell
17,671
-3,309
-16% -$230K ﹤0.01% 947
2013
Q3
$1.59M Buy
20,980
+2,838
+16% +$226K ﹤0.01% 871
2013
Q2
$1.45M Buy
+18,142
New +$1.34M ﹤0.01% 874

Other funds holding VRTX

PNC Financial Services Group's VRTX Position: Q1 2026 in Review

PNC Financial Services Group increased its Vertex Pharmaceuticals (VRTX) stake by 3.6% in Q1 2026, buying an estimated $1.17M and bringing the position to 71,942 shares worth $32.1M. The position accounts for 0.02% of the portfolio, ranked #357.

PNC Financial Services Group first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $37.9M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • PNC Financial Services Group held 71,942 shares of Vertex Pharmaceuticals worth $32.1M as of Q1 2026.
  • PNC Financial Services Group bought 2,517 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.17M.
  • Vertex Pharmaceuticals made up 0.02% of PNC Financial Services Group's portfolio in Q1 2026, its #357 holding.
  • PNC Financial Services Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • PNC Financial Services Group's Vertex Pharmaceuticals position peaked at $37.9M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.